All Posts: Georgetown Lombardi
-
A Sabbatical … Just What the Doctor Ordered
Category: GUMC Stories
-
Patient Groups Untested in Cancer Immunotherapy Trials Found to Also Benefit
Category: News Release
-
Georgetown University’s Cancer Center Receives Coveted ‘Comprehensive Cancer Center’ Status from the National Cancer Institute
Category: News Release
-
How a Comprehensive Cancer Center Makes a Difference in Patient Care
(April 26, 2019) — After being diagnosed with chronic lymphocytic leukemia (CLL) in 2009, Geoff Grubbs’ search for an expert led him to medical oncologist Bruce Cheson, MD, head of hematology and director of hematology research at Georgetown Lombardi. That connection became indispensable years later when Grubbs developed an extremely rare complication from the disease. […]
Category: GUMC Stories
-
Washington Women Raise $735K for Breast Cancer Research at Georgetown Lombardi
Category: News Release
-
Continence Confidence: Prostatectomy Patients Reporting ‘Startling’ Success After Robotic Retzius-Sparing Surgery
Category: GUMC Stories
-
Georgetown Lombardi Team Takes on 50-Hour Challenge to Win Hyundai Research Funding — and a Car!
Category: GUMC Stories
-
Georgetown Lombardi Director Louis Weiner Receives AACR 2019 Distinguished Public Service Award
Category: News Release
-
Going with Your Gut: Exploring the Microbiota’s Role in Colorectal Cancer Among the Young
(March 26, 2019) — When figures released by the American Cancer Society in 2017 showed a rise in colorectal cancer cases and deaths among young people, Benjamin Weinberg, MD, was alarmed, but not surprised. The young medical oncologist at Georgetown Lombardi Comprehensive Cancer Center is accustomed to treating men and women in their 60s and […]
Category: GUMC Stories
-
Georgetown-Led Study Leads to First FDA-Approved Drug in Decades to Improve Survival in Small Cell Lung Cancer
MEDIA CONTACT:Karen Teberkm463@georgetown.edu WASHINGTON (March 18, 2019) — The U.S. Food and Drug Administration’s approval today of atezolizumab (Tecentriq®, Genentech) in combination with chemotherapy (carboplatin and etoposide) for the initial treatment of extensive-stage small cell lung cancer (SCLC) marks the end of numerous failed attempts to improve survival for those with the deadly disease. “Atezolizumab, […]
Category: News Release